Taken together, these data indicate that the combination of LCL161 and paclitaxel inhibits tumor growth by degrading cIAP1 and cIAP2 and activating caspase-3 in a NSCLC xenograft model. This evidence concerns the gene CASP3 and non-small cell lung carcinoma.